de Pouvourville, Gérard http://orcid.org/0000-0002-5941-6823
Breau-Brunel, Manon http://orcid.org/0000-0002-1684-4238
Loncle-Provot, Véronique http://orcid.org/0000-0002-6397-7922
Beck, Ekkehard http://orcid.org/0000-0002-2022-9190
Gaugain, Loïg http://orcid.org/0000-0001-7850-4311
Nachbaur, Gaëlle http://orcid.org/0000-0001-5116-0723
Pribil, Céline http://orcid.org/0000-0002-3126-0572
Funding for this research was provided by:
GlaxoSmithKline Biologicals SA
Article History
Accepted: 20 March 2024
First Online: 23 May 2024
Declarations
:
: This was a non-interventional study without the participation of human subjects. No ethics approval was required. The study only used anonymized patient data and was compliant with procedures outlined by the National Commission on Informatics and Liberty (<i>Commission Nationale de l'Informatique et des Libertés</i> – <i>CNIL</i>).
: This was a non-interventional study which did not enroll patients. No informed consent was required.
: GdP received personal consulting fees from GSK for his involvement in advisory boards on health economic studies related to MenB (related to the present publication) and other vaccines. GdP also received honoraria from GSK for a press conference on MenB vaccination. MBB and LG are employees of Amaris Consulting. Amaris Consulting received financial compensation from GSK for performing the study related to this publication. VLP, EB, CP and GN are employed by and hold shares in GSK. The authors declare no other financial and non-financial relationships and activities.
: This was a non-interventional study which did not enroll patients. No informed consent was required.
: GlaxoSmithKline Biologicals SA funded this study (GSK study identifier: VEO 000057) and was involved in all stages of study conduct, including analysis of the data. GlaxoSmithKline Biologicals SA also took charge of all costs associated with the development and publication of this manuscript.
: All authors participated in the design, implementation, analysis, and interpretation of the study and the development of this manuscript. All authors had full access to the data and gave final approval before submission. All authors agree to be accountable for all aspects of the work.
: GSK makes available anonymized individual participant data and associated documents from interventional clinical studies which evaluate medicines, upon approval of proposals submitted to . To access data for other types of GSK-sponsored research, for study documents without patient-level data and for clinical studies not listed, please submit an enquiry via the website.
: The invasive meningococcal disease dynamic transmission model was programmed in MS Excel 2016 and updated in Excel Office 365. The model was developed by GSK and is proprietary in nature. Further information is available upon request from the corresponding author.